Clinical study of the mechanism of the lung-intestine connection based on the theory of treating the intestine for acute exacerbation of chronic obstructive pulmonary disease (COPD)

Clinical study of treating the intestine for chronic obstructive pulmonary disease (COPD) based on the mechanism of the lung-intestine connection

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-09000533

Enrollment

Unknown

Registered

2009-09-15

Start date

2008-09-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute exacerbation of chronic obstructive pulmonary disease(COPD)

Interventions

A:Basic western medical treatment plus TCM herbal intestinal granules

B:Medical treatment plus placebo

C:Basic western medical treatment plus TCM herbal lung granules

D:Basic western medical treatment plus TCM herbal both lung and intestinal granules

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with acute exacerbations of COPD; 2. TCM syndrome differentiation of lung phlegm heat syndrome, and no obvious clinical manifestations of diarrhea (stool frequency >3 times/day); 3. Age range between 18 and 75 years; 4. Onset of acute exacerbation of COPD treatment duration of 5 days or less, and COPD stage II or stage III; 5. Signed and dated written informed consent obtained from the subject and/or subject's legally acceptable representative prior to study participation.

Exclusion criteria

Exclusion criteria: 1. Patients with stage IV COPD; 2. Patients with airflow limitation due to bronchiectasis, cystic fibrosis, active tuberculosis, lung cancer, and other respiratory diseases; 3. Complication of acute left heart failure, acute cerebral hemorrhage, gastroinestinal bleeding, aplastic anemia, acute renal failure, or other serious fatal illness; 4.Complication of hypertension, coronary heart disease, diabetes, or patients deemed in unstable condition at time of presentation; 5. Comorbidity of mental illness, severe neurologic impairment (such as aphasia, agnosia), or for other reasons unable to cooperate with investigators; 6. Primary heart, liver, kidney, or hematopoietic system illnesses; 7. Recent use of immunosuppressive agents; 8. Patients with drug allergy or known allergy to components of drugs used in this study; 9. Women who are pregnant or breast-feeding; 10. Patients who have used tongfu type purgative or clear heat-phlegm type of traditional medicine within 5 days of enrollment in this study.

Design outcomes

Primary

Measure	Time frame
Pulmonary function;TCM symptoms; syndrome scores of TCM;	—

Secondary

Measure	Time frame
Blood gas analysis;	—

Countries

China

Contacts

Public ContactYuhang Li

liyuhang@bucm.edu.cn+86 010 64287002

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026